mitomycin has been researched along with Neutropenia in 38 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors." | 9.16 | Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 9.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 9.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| " The aim of the present study was to evaluate the effectiveness and safety of a combined-treatment modality consisting of systemic chemotherapy with 24-h continuous infusional gemcitabine and mitomycin C, plus external beam radiotherapy in patients with localized unresectable adenocarcinoma of the pancreas." | 9.09 | Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. ( Kornek, GV; Kraus, G; Pötter, R; Rogy, M; Scheithauer, W; Schratter, A; Selzer, E; Ulrich-Pur, H, 2001) |
| "During heated intraperitoneal chemotherapy (HIPEC), neutropenia rates of 20 to 40% have been reported when mitomycin C (MMC) is dosed by weight or body surface area (BSA)." | 7.85 | Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C. ( Aycart, SN; Bhagwandin, S; Feferman, Y; Feingold, D; Kim, J; Labow, DM; Sarpel, U, 2017) |
| " Mitomycin C (MMC) is frequently used but not devoid of toxicity, of which the most common and feared is neutropenia." | 7.81 | Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy. ( Brigand, C; Brumaru, D; Kemmel, V; Lessinger, JM; Mercoli, HA; Meyer, N; Romain, B, 2015) |
| "Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC)." | 7.80 | The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. ( Bruin, S; D'Hoore, A; Fieuws, S; Hompes, D; Mirck, B; Verwaal, V; Wolthuis, A, 2014) |
| "Patients with advanced breast cancer were randomised to 3M (mitozantrone 6." | 6.67 | Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial. ( Barton, C; Bliss, JM; Bower, M; Coombes, RC; Ford, HT; Gazet, JC; Law, M; Stein, RC, 1992) |
| "A total of 124 colorectal cancer patients who underwent CRS with HIPEC between March 2015 and January 2019 were evaluated." | 5.72 | Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis. ( Baik, SH; Jeon, Y; Kang, J; Lee, HW; Lee, SJ; Park, EJ, 2022) |
| "Neutropenia is a frequent complication associated with MMC-HIPEC." | 5.35 | Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. ( Armstrong, TS; Eng, C; Gonzalez-Moreno, S; Katz, MH; Lambert, DH; Lambert, LA; Lee, JJ; Liu, S; Mansfield, PF; Tansey, P; Tortorice, ML; Wolff, RA, 2009) |
| "The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors." | 5.16 | Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012) |
| "We conducted a phase I/II study investigating synchronous chemoradiotherapy with mitomycin C and infusional 5-fluorouracil (5-FU) in muscle invasive bladder cancer." | 5.11 | Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Peake, DR; Stocken, DD; Wallace, DM; Zarkar, A, 2004) |
| "The aim of this study was to evaluate the activity and toxicity of a combination regimen of CPT-11 and mitomycin-c as second-line chemotherapy for pretreated patients with advanced, metastatic, or both, gastric adenocarcinoma." | 5.11 | Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). ( Battaglia, C; Colucci, G; Di Bisceglie, M; Gebbia, N; Gebbia, V; Giuliani, F; Maiello, E; Molica, S; Vinciarelli, G, 2005) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 5.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 5.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| " The aim of the present study was to evaluate the effectiveness and safety of a combined-treatment modality consisting of systemic chemotherapy with 24-h continuous infusional gemcitabine and mitomycin C, plus external beam radiotherapy in patients with localized unresectable adenocarcinoma of the pancreas." | 5.09 | Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. ( Kornek, GV; Kraus, G; Pötter, R; Rogy, M; Scheithauer, W; Schratter, A; Selzer, E; Ulrich-Pur, H, 2001) |
| "During heated intraperitoneal chemotherapy (HIPEC), neutropenia rates of 20 to 40% have been reported when mitomycin C (MMC) is dosed by weight or body surface area (BSA)." | 3.85 | Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C. ( Aycart, SN; Bhagwandin, S; Feferman, Y; Feingold, D; Kim, J; Labow, DM; Sarpel, U, 2017) |
| "Fifty-six anal cancer patients from 2 institutions received definitive radiation therapy (median primary dose of 54 Gy) using intensity modulated radiation therapy (IMRT, n=49) or 3-dimensional (3D) conformal therapy (n=7) with concurrent 5-fluorouracil (5-FU) and mitomycin C." | 3.85 | Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. ( Aggarwal, S; Bazan, JG; Chang, DT; Golden, DW; Kopec, M; Lee, AY; Liauw, SL; Pelizzari, CA, 2017) |
| "The cohort included 45 patients with nonmetastatic anal cancer who underwent FDG-PET imaging prior to definitive chemoradiation with mitomycin-C and 5-fluorouracil." | 3.83 | Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation. ( Allen, JN; Blaszkowsky, LS; Drapek, LC; Hong, TS; Jee, KW; Lee, LK; Murphy, JE; Niemierko, A; Rose, BS; Wang, Y; Wo, JY, 2016) |
| " Mitomycin C (MMC) is frequently used but not devoid of toxicity, of which the most common and feared is neutropenia." | 3.81 | Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy. ( Brigand, C; Brumaru, D; Kemmel, V; Lessinger, JM; Mercoli, HA; Meyer, N; Romain, B, 2015) |
| "Previously, a pilot genome-wide association study has identified candidate single nucleotide polymorphism predictors for the therapeutic response of 5-fluorouracil, mitoxantrone and cisplatin (FMP) combination chemotherapy in advanced hepatocellular carcinoma (HCC)." | 3.80 | A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. ( Chang, ML; Hsu, CL; Hung, CF; Liang, KH; Lin, CC; Yeh, CT, 2014) |
| "Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC)." | 3.80 | The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. ( Bruin, S; D'Hoore, A; Fieuws, S; Hompes, D; Mirck, B; Verwaal, V; Wolthuis, A, 2014) |
| "Accurate description of current practice within advanced colorectal cancer (CRC) specialties were needed to inform an economic evaluation of the UGT1A1 pharmacogenetic test for irinotecan in the United Kingdom." | 3.76 | Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. ( Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW, 2010) |
| "8 mg/kg in combination with RT treatment is safe, with a high rate of tumor control." | 3.30 | Pegylated Liposomal Mitomycin C Lipidic Prodrug in Combination With External Beam Radiation Therapy in Patients With Advanced Cancer: A Phase 1B Study. ( Amitay, Y; Corn, B; Gabizon, A; Levy, A; Ohana, P; Pfeffer, R; Purim, O; Sapir, E; Wygoda, M, 2023) |
| "Grade 3/4 neutropenia was observed in 21 % of patients and grade 3/4 febrile neutropenia was seen in only one patient." | 2.73 | Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. ( Ahn, JS; Ahn, MJ; Hwang, IG; Im, YH; Kang, WK; Lee, SC; Lim, HY; Park, BB; Park, K, 2008) |
| "169 patients with radically resected gastric cancer were randomized to receive CPT-11 (180 mg/m2 day 1), leucovorin (100 mg/m2 days 1-2), FU (400-600 mg/m2 days 1-2, q 14; for four cycles; FOLFIRI regimen), followed by docetaxel (85 mg/m2 day 1), cisplatin (75 mg/m2 day 1, q 21; for three cycles; arm A), or MMC (8 mg/m2 days 1-2 as 2-hour infusion, q 42; for four cycles; arm B)." | 2.72 | Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. ( Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N, 2006) |
| "Patients with advanced breast cancer were randomised to 3M (mitozantrone 6." | 2.67 | Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial. ( Barton, C; Bliss, JM; Bower, M; Coombes, RC; Ford, HT; Gazet, JC; Law, M; Stein, RC, 1992) |
| "A total of 124 colorectal cancer patients who underwent CRS with HIPEC between March 2015 and January 2019 were evaluated." | 1.72 | Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis. ( Baik, SH; Jeon, Y; Kang, J; Lee, HW; Lee, SJ; Park, EJ, 2022) |
| "Locally advanced anal cancer patients, especially with T4 disease and fistula, have a dismal prognosis." | 1.46 | Early closure of fistula using neo-adjuvant intra-arterial chemotherapy in locally advanced anal cancer. ( Allal, AS; Cacheux, W; Dietrich, PY; Fernandez, E; Ho, L; Koessler, T; Puppa, G; Ris, F; Roche, B; Roth, A; Zilli, T, 2017) |
| "Grade 3-4 neutropenia was seen in 10/23 patients (43%)." | 1.46 | PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. ( Beer, J; Bodis, S; Oehler, C; Vlachopoulou, V; von Moos, R; Zimmermann, M; Zwahlen, DR, 2017) |
| "Neutropenia is a frequent complication associated with MMC-HIPEC." | 1.35 | Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. ( Armstrong, TS; Eng, C; Gonzalez-Moreno, S; Katz, MH; Lambert, DH; Lambert, LA; Lee, JJ; Liu, S; Mansfield, PF; Tansey, P; Tortorice, ML; Wolff, RA, 2009) |
| "We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy." | 1.35 | Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. ( Aydogan, B; Chmura, SJ; Devisetty, K; Jani, AB; Kindler, HL; Mell, LK; Miller, RC; Mundt, AJ; Roeske, JC; Salama, JK; Schomas, DA, 2008) |
| "In patients with pancreatic cancer, the overall response rate was 42% with a median survival of 8 months." | 1.31 | Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen. ( Gallagher, CJ; Shamash, J; Slater, S; Slevin, ML; Wilson, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.26) | 18.7374 |
| 1990's | 8 (21.05) | 18.2507 |
| 2000's | 14 (36.84) | 29.6817 |
| 2010's | 11 (28.95) | 24.3611 |
| 2020's | 3 (7.89) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, SJ | 2 |
| Jeon, Y | 1 |
| Lee, HW | 1 |
| Kang, J | 1 |
| Baik, SH | 2 |
| Park, EJ | 2 |
| Sapir, E | 1 |
| Pfeffer, R | 1 |
| Wygoda, M | 1 |
| Purim, O | 1 |
| Levy, A | 1 |
| Corn, B | 1 |
| Amitay, Y | 1 |
| Ohana, P | 1 |
| Gabizon, A | 1 |
| Zimmermann, M | 1 |
| Beer, J | 1 |
| Bodis, S | 1 |
| von Moos, R | 1 |
| Vlachopoulou, V | 1 |
| Zwahlen, DR | 1 |
| Oehler, C | 1 |
| Cacheux, W | 1 |
| Koessler, T | 1 |
| Puppa, G | 1 |
| Fernandez, E | 1 |
| Ho, L | 1 |
| Dietrich, PY | 1 |
| Zilli, T | 1 |
| Allal, AS | 2 |
| Roche, B | 1 |
| Ris, F | 1 |
| Roth, A | 1 |
| Feferman, Y | 1 |
| Bhagwandin, S | 1 |
| Kim, J | 1 |
| Aycart, SN | 1 |
| Feingold, D | 1 |
| Labow, DM | 1 |
| Sarpel, U | 1 |
| Yeh, CT | 1 |
| Liang, KH | 1 |
| Lin, CC | 1 |
| Chang, ML | 1 |
| Hsu, CL | 1 |
| Hung, CF | 1 |
| Bazan, JG | 2 |
| Luxton, G | 1 |
| Kozak, MM | 1 |
| Anderson, EM | 1 |
| Hancock, SL | 1 |
| Kapp, DS | 1 |
| Kidd, EA | 1 |
| Koong, AC | 1 |
| Chang, DT | 2 |
| Hompes, D | 1 |
| D'Hoore, A | 1 |
| Wolthuis, A | 1 |
| Fieuws, S | 1 |
| Mirck, B | 1 |
| Bruin, S | 1 |
| Verwaal, V | 1 |
| Kemmel, V | 1 |
| Mercoli, HA | 1 |
| Meyer, N | 1 |
| Brumaru, D | 1 |
| Romain, B | 1 |
| Lessinger, JM | 1 |
| Brigand, C | 1 |
| Rose, BS | 1 |
| Jee, KW | 1 |
| Niemierko, A | 1 |
| Murphy, JE | 1 |
| Blaszkowsky, LS | 1 |
| Allen, JN | 1 |
| Lee, LK | 1 |
| Wang, Y | 1 |
| Drapek, LC | 1 |
| Hong, TS | 1 |
| Wo, JY | 1 |
| Lee, AY | 1 |
| Golden, DW | 1 |
| Kopec, M | 1 |
| Pelizzari, CA | 1 |
| Aggarwal, S | 1 |
| Liauw, SL | 1 |
| Lambert, LA | 1 |
| Armstrong, TS | 1 |
| Lee, JJ | 1 |
| Liu, S | 1 |
| Katz, MH | 1 |
| Eng, C | 1 |
| Wolff, RA | 1 |
| Tortorice, ML | 1 |
| Tansey, P | 1 |
| Gonzalez-Moreno, S | 1 |
| Lambert, DH | 1 |
| Mansfield, PF | 1 |
| Li, M | 1 |
| Zhang, J | 1 |
| Wang, D | 1 |
| Zhong, B | 1 |
| Tucker, S | 1 |
| Lu, C | 1 |
| Cheng, J | 1 |
| Cao, C | 1 |
| Xu, J | 2 |
| Pan, H | 1 |
| Shabaruddin, FH | 1 |
| Elliott, RA | 1 |
| Valle, JW | 1 |
| Newman, WG | 1 |
| Payne, K | 1 |
| Lim, KH | 1 |
| Han, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Bang, YJ | 1 |
| Francini, G | 1 |
| Petrioli, R | 1 |
| Messinese, S | 1 |
| Pozzessere, D | 1 |
| Marsili, S | 1 |
| Correale, P | 1 |
| Sabatino, M | 1 |
| Fiaschi, AI | 1 |
| Slater, S | 1 |
| Shamash, J | 1 |
| Wilson, P | 1 |
| Gallagher, CJ | 1 |
| Slevin, ML | 1 |
| Kelleher, M | 1 |
| Tebbutt, NC | 1 |
| Cunningham, D | 1 |
| Andreyev, J | 1 |
| Allen, M | 1 |
| Hill, M | 1 |
| Norman, A | 1 |
| Hussain, SA | 1 |
| Stocken, DD | 1 |
| Peake, DR | 1 |
| Glaholm, JG | 1 |
| Zarkar, A | 1 |
| Wallace, DM | 1 |
| James, ND | 1 |
| Polyzos, A | 1 |
| Koulentianos, E | 1 |
| Tzianoumis, L | 1 |
| Sfikakis, P | 1 |
| Giuliani, F | 1 |
| Molica, S | 1 |
| Maiello, E | 1 |
| Battaglia, C | 1 |
| Gebbia, V | 1 |
| Di Bisceglie, M | 1 |
| Vinciarelli, G | 1 |
| Gebbia, N | 1 |
| Colucci, G | 1 |
| Di Bartolomeo, M | 1 |
| Buzzoni, R | 1 |
| Mariani, L | 1 |
| Ferrario, E | 1 |
| Katia, D | 1 |
| Gevorgyan, A | 1 |
| Zilembo, N | 1 |
| Bordonaro, R | 1 |
| Bochicchio, AM | 1 |
| Massidda, B | 1 |
| Ardizzoia, A | 1 |
| Ardizzoni, A | 1 |
| Marini, G | 1 |
| Aitini, E | 1 |
| Schieppati, G | 1 |
| Comella, G | 1 |
| Pinotti, G | 1 |
| Palazzo, S | 1 |
| Cicero, G | 1 |
| Bajetta, E | 1 |
| Villa, E | 1 |
| Fagnani, D | 1 |
| Reguzzoni, G | 1 |
| Agostana, B | 1 |
| Oliani, C | 1 |
| Kildani, B | 1 |
| Duro, M | 1 |
| Botta, M | 1 |
| Mozzana, R | 1 |
| Mantovani, G | 1 |
| Mell, LK | 1 |
| Schomas, DA | 1 |
| Salama, JK | 1 |
| Devisetty, K | 1 |
| Aydogan, B | 1 |
| Miller, RC | 1 |
| Jani, AB | 1 |
| Kindler, HL | 1 |
| Mundt, AJ | 1 |
| Roeske, JC | 1 |
| Chmura, SJ | 1 |
| Park, BB | 1 |
| Im, YH | 1 |
| Hwang, IG | 1 |
| Lee, SC | 1 |
| Ahn, JS | 1 |
| Ahn, MJ | 1 |
| Lim, HY | 1 |
| Kang, WK | 1 |
| Park, K | 1 |
| Glynne-Jones, R | 1 |
| Meadows, H | 1 |
| Wan, S | 1 |
| Gollins, S | 1 |
| Leslie, M | 1 |
| Levine, E | 1 |
| McDonald, AC | 1 |
| Myint, S | 1 |
| Samuel, L | 1 |
| Sebag-Montefiore, D | 1 |
| Akahori, H | 1 |
| Shibuya, K | 1 |
| Ozai, M | 1 |
| Ida, M | 1 |
| Kabaya, K | 1 |
| Kato, T | 1 |
| Miyazaki, H | 2 |
| Iop, A | 1 |
| Cartei, G | 1 |
| Vigevani, E | 1 |
| Clocchiatti, L | 1 |
| Mansutti, M | 1 |
| Sibau, AM | 1 |
| Furuse, K | 2 |
| Kawahara, M | 1 |
| Nishiwaki, Y | 2 |
| Fukuoka, M | 2 |
| Takada, M | 2 |
| Miyashita, M | 1 |
| Ohashi, Y | 1 |
| Anderson, N | 1 |
| Lokich, J | 1 |
| Moore, C | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| Hosomi, Y | 1 |
| Ohe, Y | 1 |
| Mito, K | 1 |
| Uramoto, H | 1 |
| Moriyama, E | 1 |
| Tanaka, K | 1 |
| Kodama, K | 1 |
| Niho, S | 1 |
| Goto, K | 1 |
| Ohmatsu, H | 1 |
| Matsumoto, T | 1 |
| Hojo, F | 1 |
| Kakinuma, R | 1 |
| Roth, AD | 1 |
| Berney, CR | 1 |
| Rohner, S | 1 |
| Morel, P | 1 |
| Marti, MC | 1 |
| Aapro, MS | 1 |
| Alberto, P | 1 |
| Kornek, GV | 1 |
| Pötter, R | 1 |
| Selzer, E | 1 |
| Schratter, A | 1 |
| Ulrich-Pur, H | 1 |
| Rogy, M | 1 |
| Kraus, G | 1 |
| Scheithauer, W | 1 |
| Yamao, T | 1 |
| Shirao, K | 1 |
| Matsumura, Y | 1 |
| Muro, K | 1 |
| Yamada, Y | 1 |
| Goto, M | 1 |
| Chin, K | 1 |
| Shimada, Y | 1 |
| Ariyoshi, Y | 1 |
| Niitani, H | 1 |
| Ota, K | 1 |
| Motomiya, M | 1 |
| Hasegawa, K | 1 |
| Tominaga, K | 1 |
| Kuriyama, T | 1 |
| Stein, RC | 1 |
| Bower, M | 1 |
| Law, M | 1 |
| Bliss, JM | 1 |
| Barton, C | 1 |
| Gazet, JC | 1 |
| Ford, HT | 1 |
| Coombes, RC | 1 |
| Erlichman, C | 1 |
| Rauth, AM | 1 |
| Battistella, R | 1 |
| Fine, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial to Analyze Clinical and Pharmacological Properties for Severe Neutropenia After Cytoreductive Surgery Followed by Hyperthermic Intraperitoneal Chemotherapy Using Mitomycin-C[NCT05513183] | 74 participants (Actual) | Observational | 2021-05-20 | Completed | |||
| Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951] | Phase 2/Phase 3 | 358 participants (Anticipated) | Interventional | 2017-06-01 | Recruiting | ||
| A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mitomycin and Neutropenia
| Article | Year |
|---|---|
Physiologic role of TPO in thrombopoiesis.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Dose-Response Relationship, Drug; Fetal Blood; Hemo | 1996 |
18 trials available for mitomycin and Neutropenia
| Article | Year |
|---|---|
Pegylated Liposomal Mitomycin C Lipidic Prodrug in Combination With External Beam Radiation Therapy in Patients With Advanced Cancer: A Phase 1B Study.
Topics: Humans; Lipids; Mitomycin; Neoplasms; Neutropenia; Polyethylene Glycols; Prodrugs | 2023 |
A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2009 |
Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Diseas | 2012 |
Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2002 |
Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Fema | 2003 |
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Modalit | 2004 |
Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2005 |
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2006 |
Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2008 |
EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2008 |
Phase I/II study of vinorelbine, mitomycin, and cisplatin for stage IIIB or IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dis | 1999 |
Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Doc | 1999 |
Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Arteries; Bleo | 2000 |
Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deo | 2001 |
Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response R | 2001 |
The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribut | 1992 |
Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Methotrexate; Midd | 1992 |
19 other studies available for mitomycin and Neutropenia
| Article | Year |
|---|---|
Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis.
Topics: Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthe | 2022 |
ASO Author Reflections: Delayed Occurrence and Postoperative Risks of Mitomycin-C-Induced Neutropenia After Hyperthermic Intraperitoneal Chemotherapy.
Topics: Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthermia, Induced; Hyperth | 2022 |
PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2017 |
Early closure of fistula using neo-adjuvant intra-arterial chemotherapy in locally advanced anal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Chemoradioth | 2017 |
Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Che | 2017 |
A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F | 2014 |
Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Bone Marrow; Chemoradiotherapy; Cisplatin; Drug Adminis | 2013 |
The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Blood Loss, Surgical; Chemotherapy, Ca | 2014 |
Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2015 |
Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation.
Topics: Adult; Aged; Antineoplastic Agents; Anus Neoplasms; Bone Marrow; Chemoradiotherapy; Cohort Studies; | 2016 |
Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow; | 2017 |
Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Combined Modality Therapy; Female; | 2009 |
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; | 2010 |
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2002 |
Increased dosage of epirubicin and mitomycin-C for the treatment of metastatic adenocarcinoma of unknown primary site.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Biopsy; Dose-Response Relationship, Drug; Epirubicin; H | 1989 |
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplas | 2008 |
Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
Topics: Animals; Disease Models, Animal; Granulocyte Colony-Stimulating Factor; Humans; Male; Mice; Mice, In | 1996 |
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1997 |
Mitomycin C pharmacokinetics in patients with recurrent or metastatic colorectal carcinoma.
Topics: Aged; Chromatography, High Pressure Liquid; Colonic Neoplasms; Half-Life; Humans; Kidney; Kinetics; | 1987 |